InterMune Price Target Increased to $19.00 by Analysts at UBS AG (ITMN)
Analysts at UBS AG hoisted their price target on shares of InterMune (NASDAQ:ITMN) from $15.00 to $19.00 in a research report issued to clients and investors on Friday, Analyst Ratings Network.com reports. UBS AG’s target price would suggest a potential upside of 14.67% from the stock’s previous close.
InterMune (NASDAQ:ITMN) opened at 16.57 on Friday. InterMune has a one year low of $8.21 and a one year high of $16.88. The stock has a 50-day moving average of $14.14 and a 200-day moving average of $13.83. The company’s market cap is $1.359 billion.
InterMune (NASDAQ:ITMN) last posted its quarterly earnings results on Wednesday, October 30th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.10. The company had revenue of $19.72 million for the quarter, compared to the consensus estimate of $16.44 million. During the same quarter last year, the company posted ($0.63) earnings per share. InterMune’s revenue was up 161.9% compared to the same quarter last year. Analysts expect that InterMune will post $-2.71 EPS for the current fiscal year.
A number of other firms have also recently commented on ITMN. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of InterMune in a research note to investors on Friday, November 1st. They now have a $17.00 price target on the stock. Separately, analysts at Stifel Nicolaus raised their price target on shares of InterMune from $18.00 to $20.00 in a research note to investors on Friday, November 1st. They now have a “buy” rating on the stock. Finally, analysts at Leerink Swann raised their price target on shares of InterMune from $16.00 to $17.00 in a research note to investors on Thursday, October 31st. They now have an “outperform” rating on the stock. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $17.63.
InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.